Simulations Plus Upgrades Flagship GastroPlus
June 18 2019 - 8:30AM
Business Wire
User- and collaboration-driven functionality
in version 9.7 expands the science of local and systemic
exposure
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced that it has released version 9.7 of its flagship
physiologically based pharmacokinetic (PBPK) modeling
platform, GastroPlus®.
Key improvements in this version include:
- Ability to add lysosomal trapping
effects to PBPK tissues for more accurate systemic
calculations
- New mechanistic pregnancy PBPK model
with integrated population settings
- Options to define multiple solubility
inputs for different drug forms
- Expanded fed state simulation
conditions based on defined meal types
- Validated models of standard compounds
added to the drug-drug interaction (DDI) Module
- PK/PD model extensions added to the
PDPlus™ Module
- Improved population groups for
extensive, intermediate, and poor metabolizers based on specific
genotypes
- Updates to the dermal absorption
(TCAT™) model through the Cosmetics Europe collaboration
- Novel effects of immune response added
to the intramuscular injection models
- And more...
“Special populations modeling continues to be a key component of
GastroPlus with numerous companies applying the results to support
regulatory interactions,” said Dr. Viera Lukacova, director of
Simulation Sciences for Simulations Plus. “With this release, we
have added several new groups, including a validated mechanistic
pregnancy model, which will greatly enhance the understanding of
drug exposure and assist with dose selection decisions. Special
thanks to the dedicated scientific team at Simulations Plus and our
collaboration partners for all their outstanding efforts.”
John DiBella, Lancaster division president for Simulations Plus,
added: “GastroPlus continues to provide researchers, including
chemists, DMPK scientists, pharmaceutical developers, and clinical
pharmacologists, a proven and flexible PBPK software to support
safety and efficacy decisions, first-in-human estimations,
formulation optimization, and drug-drug interaction assessments.
For over twenty years, Simulations Plus has been dedicated to
improving our state-of-the-art tools, and the significant
enhancements that are integrated in version 9.7 are just a preview
of exciting advancements that will be the foundation for next
year’s entirely new platform release of GastroPlus.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services
for regulatory submissions and quantitative systems
pharmacology models for drug-induced liver injury
and nonalcoholic fatty liver disease. The company is a global
leader focused on improving the ways scientists use knowledge and
data to predict the properties and outcomes of pharmaceutical,
biotechnology, and chemical agents. Our software is licensed and
used in the conduct of drug research by major pharmaceutical,
biotechnology, chemical, and consumer goods companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us
on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190618005020/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.com
Hayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024